Gu L - Search Results

1

Novel Peptide Therapeutic Approaches for Cancer Treatment.

Li CM, Haratipour P, Lingeman RG, Perry JJP, Gu L, Hickey RJ, Malkas LH. Li CM, et al. Among authors: gu l. Cells. 2021 Oct 27;10(11):2908. doi: 10.3390/cells10112908. Cells. 2021. PMID: 34831131 Free PMC article. Review.

2

A PCNA-derived cell permeable peptide selectively inhibits neuroblastoma cell growth.

Gu L, Smith S, Li C, Hickey RJ, Stark JM, Fields GB, Lang WH, Sandoval JA, Malkas LH. Gu L, et al. PLoS One. 2014 Apr 11;9(4):e94773. doi: 10.1371/journal.pone.0094773. eCollection 2014. PLoS One. 2014. PMID: 24728180 Free PMC article.

3

A Peptide mimicking a region in proliferating cell nuclear antigen specific to key protein interactions is cytotoxic to breast cancer.

Smith SJ, Gu L, Phipps EA, Dobrolecki LE, Mabrey KS, Gulley P, Dillehay KL, Dong Z, Fields GB, Chen YR, Ann D, Hickey RJ, Malkas LH. Smith SJ, et al. Among authors: gu l. Mol Pharmacol. 2015 Feb;87(2):263-76. doi: 10.1124/mol.114.093211. Epub 2014 Dec 5. Mol Pharmacol. 2015. PMID: 25480843 Free PMC article.

4

The Mechanism by Which MYCN Amplification Confers an Enhanced Sensitivity to a PCNA-Derived Cell Permeable Peptide in Neuroblastoma Cells.

Gu L, Chu P, Lingeman R, McDaniel H, Kechichian S, Hickey RJ, Liu Z, Yuan YC, Sandoval JA, Fields GB, Malkas LH. Gu L, et al. EBioMedicine. 2015 Nov 10;2(12):1923-31. doi: 10.1016/j.ebiom.2015.11.016. eCollection 2015 Dec. EBioMedicine. 2015. PMID: 26844271 Free PMC article.

5

The Anticancer Activity of a First-in-class Small-molecule Targeting PCNA.

Gu L, Lingeman R, Yakushijin F, Sun E, Cui Q, Chao J, Hu W, Li H, Hickey RJ, Stark JM, Yuan YC, Chen Y, Vonderfecht SL, Synold TW, Shi Y, Reckamp KL, Horne D, Malkas LH. Gu L, et al. Clin Cancer Res. 2018 Dec 1;24(23):6053-6065. doi: 10.1158/1078-0432.CCR-18-0592. Epub 2018 Jul 2. Clin Cancer Res. 2018. PMID: 29967249 Free PMC article.

6

Arginine shortage induces replication stress and confers genotoxic resistance by inhibiting histone H4 translation and promoting PCNA ubiquitination.

Wang YC, Kelso AA, Karamafrooz A, Chen YH, Chen WK, Cheng CT, Qi Y, Gu L, Malkas L, Taglialatela A, Kung HJ, Moldovan GL, Ciccia A, Stark JM, Ann DK. Wang YC, et al. Among authors: gu l. Cell Rep. 2023 Apr 25;42(4):112296. doi: 10.1016/j.celrep.2023.112296. Epub 2023 Mar 23. Cell Rep. 2023. PMID: 36961817 Free PMC article.

7

Therapeutic Targeting of DNA Replication Stress in Cancer.

Gu L, Hickey RJ, Malkas LH. Gu L, et al. Genes (Basel). 2023 Jun 26;14(7):1346. doi: 10.3390/genes14071346. Genes (Basel). 2023. PMID: 37510250 Free PMC article. Review.

8

Small molecule targeting of transcription-replication conflict for selective chemotherapy.

Gu L, Li M, Li CM, Haratipour P, Lingeman R, Jossart J, Gutova M, Flores L, Hyde C, Kenjić N, Li H, Chung V, Li H, Lomenick B, Von Hoff DD, Synold TW, Aboody KS, Liu Y, Horne D, Hickey RJ, Perry JJP, Malkas LH. Gu L, et al. Cell Chem Biol. 2023 Oct 19;30(10):1235-1247.e6. doi: 10.1016/j.chembiol.2023.07.001. Epub 2023 Aug 1. Cell Chem Biol. 2023. PMID: 37531956 Free PMC article.

9

The potential of PCNA inhibition as a therapeutic strategy in cervical cancer.

Wendel SO, Snow JA, Gu L, Banerjee NS, Malkas L, Wallace NA. Wendel SO, et al. Among authors: gu l. J Med Virol. 2023 Nov;95(11):e29244. doi: 10.1002/jmv.29244. J Med Virol. 2023. PMID: 38010649 Review.

10

Darpp-32 and its truncated variant t-Darpp have antagonistic effects on breast cancer cell growth and herceptin resistance.

Gu L, Waliany S, Kane SE. Gu L, et al. PLoS One. 2009 Jul 13;4(7):e6220. doi: 10.1371/journal.pone.0006220. PLoS One. 2009. PMID: 19593441 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

6,549 results

Search Page